Research guide · Skin

GHK-Cu
research guide

A copper-binding tripeptide first isolated from human plasma, and a cosmetic ingredient listed as copper tripeptide-1. Here is what has been studied, in what, and where the evidence runs out.

Reading time6 min
ClassCopper tripeptide complex
Evidence gradeEarly human (topical)

Written by 6AM Research · 18 Nov 2026. This guide summarises research. It is not medical advice.

GHK-CU
1973first isolated from human plasma by Pickart
Topical only controlled human data cover skin application
Short answerResearch guide · 6 min read · Updated 18 Nov 2026

GHK-Cu is a three-amino-acid peptide, GHK (glycine–histidine–lysine), bound to copper(II). In cosmetics it is listed as copper tripeptide-1. Its research is mostly cell and animal studies. The human studies applied it to the skin, most were conference posters or pilot reports, and the one PubMed-indexed randomised trial of a skin-care regimen found no objective difference from the comparison routine. No medicine containing it appears in Drugs@FDA.

Key takeaways

  • GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma in 1973.
  • Most research is in cell cultures and animals. The small human skin studies are known mainly through a 2018 review by GHK’s discoverer.
  • The human studies applied it to the skin; most were conference posters or pilot reports. The one PubMed-indexed randomised trial of a skin-care regimen found no objective difference from the comparison routine.
  • We found no controlled trial of injected GHK-Cu, published or registered. FDA says there are limited human data on injectable GHK-Cu.
  • No medicine containing it appears in Drugs@FDA. As a cosmetic ingredient it needs no FDA approval; FDA says a product’s status “is determined by a product’s intended use”.

01What is GHK-Cu?

GHK-Cu is a three-amino-acid peptide, GHK (glycine–histidine–lysine), bound to copper(II). GHK has a high affinity for copper(II). It was first isolated in 1973 as a factor in human plasma that changed protein synthesis in liver tissue.

Plasma levels of GHK are reported to decline with age, one reason it attracted interest in aging-skin research.

02Has GHK-Cu been studied in humans?

Cell studies
Extensive
Animal studies
Moderate
Human pilot / case series
Limited
Controlled human trials
Minimal
Regulatory approval
None

The controlled human studies applied it to the skin. We found no controlled trial of injected GHK-Cu, published or registered (PubMed and ClinicalTrials.gov, 18 Nov 2026).

Sources: Pickart & Margolina, Int J Mol Sci, 2018; registry and PubMed searches, 18 Nov 2026

03What have GHK-Cu studies measured?

Mostly cell and animal studies, plus small skin studies in people. Cell and animal findings are not evidence of an effect in people.

1
Collagen and matrix synthesis

Stimulation of collagen, elastin and glycosaminoglycan synthesis in fibroblast cultures.

2
Gene-expression signatures

Connectivity-map analyses suggest GHK shifts expression of many genes; these are computational, not clinical, findings.

3
Skin studies in people

Small studies of creams, mostly 12 weeks long, measured skin density, thickness and wrinkles; most were conference posters known through a 2018 review by GHK’s discoverer. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing (13 completers), found no objective difference from the comparison routine.

04How strong is the evidence on GHK-Cu?

Area studiedMain evidenceHuman dataGrade
Skin appearance (topical)Cell and animal studiesSmall studies, mostly conference posters; one indexed randomised trial with no objective differenceEarly human
Any route other than the skinAnimal studiesNo controlled trial foundPreclinical

05What hasn't GHK-Cu research shown?

  • That findings on skin apply to any other route. We found no controlled trial of GHK-Cu given any other way.
  • Large, independent, randomised trials of any route.
  • Long-term safety in people. For injectable GHK-Cu, FDA says “there are limited data in humans to inform safety-related considerations”.

06Is GHK-Cu an approved medicine? Status, Nov 2026

No medicine containing GHK-Cu appears in Drugs@FDA. Its status as a cosmetic ingredient and on FDA’s compounding page is set out below.

  1. CosmeticsCosmetic ingredient

    Listed in cosmetics as copper tripeptide-1. FDA says cosmetic ingredients, apart from colour additives, need no approval before sale, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”.

  2. FDA listCategory 2 nomination withdrawn

    FDA’s compounding page (content current 22 April 2026) lists GHK-Cu, for injectable routes, among substances previously in Category 2, the category for bulk substances that may present significant safety risks, whose nominations were withdrawn by the nominators. FDA’s note cites possible immune reactions from aggregation and peptide-related impurities.

  3. May 2026Category 1, except injection

    FDA’s list of nominated bulk substances (updated 14 May 2026) places GHK-Cu, except for injectable routes, in Category 1, “bulk drug substances under evaluation”. FDA had removed it on 22 April when the nominations were withdrawn; one nominator then said it had meant to withdraw only the injectable route.

  4. Jul–Oct 2026Not in the 2026 reviews

    GHK-Cu was not among the peptides on the agenda of FDA’s advisory committee in July 2026, or in HHS’s October 2026 enforcement-discretion policy. FDA says the committee will discuss GHK-Cu at a meeting before the end of February 2027.

  5. NowNo approved medicine

    No medicine containing it appears in Drugs@FDA.

07Sources

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int, 2015:648108. pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
  2. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018;19(7):1987. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
  4. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 18 Nov 2026. www.fda.gov/media/94155/download
  5. U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027; agenda includes GHK-Cu). Advisory committee page, published 15 Apr 2026; read 18 Nov 2026. www.fda.gov/advisory-committees/pharmacy-compounding-advis…
  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-…
  7. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Web page, content current as of 11 Sep 2024; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmeti…
  8. PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328
  9. ClinicalTrials.gov. Search results for “GHK-Cu” and “copper tripeptide-1”; PubMed search for controlled trials of injected GHK-Cu: none found. Registry and database searches, 18 Nov 2026. clinicaltrials.gov/search?term=GHK-Cu
  10. U.S. Food and Drug Administration. Drugs@FDA data, queried through the openFDA API for active ingredients “prezatide”, “copper tripeptide” and “GHK”: no matches. Database query, 18 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingre…
  11. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar…
  12. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcemen…

Questions about a source?

Write to 6AM Research about any study or document cited in this guide.

Write to us

Common questions

Is GHK-Cu the same as copper tripeptide-1?

Yes. Copper tripeptide-1 is the name used in cosmetic ingredient lists; prezatide copper is another name for the same complex.

Why is it blue?

The copper(II) complex gives GHK-Cu its blue colour in powder and solution.

Is GHK-Cu an approved medicine?

No medicine containing it appears in Drugs@FDA. As a cosmetic ingredient it needs no FDA approval before sale, but FDA treats a product intended to affect the body’s structure or function as a drug.

Further reading

Articles on this topic

ComparisonBPC-157 vs GHK-Cu: Identity, Evidence and StatusBPC-157 and GHK-Cu side by side: what each peptide is, how each has been studied, and its US, UK, Australian and anti-doping status, dated Nov 2026.13 min readComparisonGHK vs GHK-Cu: with and without copperGHK is copper-free; GHK-Cu is its copper complex. Compare their identity, study models and the regulatory and sport findings checked here.8 min readClaims vs evidenceGHK-Cu claims and the evidence: what studies measuredA randomized GHK-Cu skin-care study with 13 completers found no objective difference between groups. See what eyebrow, animal, and cell studies…7 min readIdentity and historyGHK-Cu History: Discovery, Names and RegulationGHK-Cu history from Pickart’s 1973 serum tripeptide to 2026: how its structure and copper binding were found, its names, and its regulatory steps.12 min readComparisonGHK-Cu vs KPV: identity, evidence and legal statusGHK-Cu is a copper complex; KPV is a three-amino-acid peptide. Their identity, human evidence and regulatory records side by side, dated 21 Nov 2026.8 min readComparisonGHK-Cu vs Matrixyl: Identity, Evidence and StatusGHK-Cu vs Matrixyl: a copper tripeptide and a palmitoyl pentapeptide. How they differ in identity, cosmetic names, evidence and regulatory status.12 min readComparisonGHK-Cu vs NAD+: identity, evidence and statusGHK-Cu is a copper–peptide complex; NAD+ is a coenzyme. Compare their identity, evidence limits and the regulatory records checked here.9 min readComparisonGHK-Cu vs “GLOW”: identity, evidence and legal statusGHK-Cu is a copper–peptide complex. “GLOW” is a blend with no direct study found. Compare human evidence, regulatory records and sport rules.8 min readComparisonGHK-Cu vs “KLOW”: identity, evidence and legal statusGHK-Cu is one peptide; “KLOW” is a seller name for a vial listing GHK-Cu, BPC-157, TB-500 and KPV. We found no study of the mix (21 Nov 2026).11 min readSport · WADAIs GHK-Cu Banned in Sport? WADA Lists 2026 and 2027WADA’s 2026 and 2027 Prohibited Lists do not name GHK-Cu, and WADA says unnamed peptides may still be prohibited. What class S0 says and who decides.9 min readLegal status · AustraliaIs GHK-Cu Legal in Australia? TGA and Cosmetics (2026)The Poisons Standard does not name GHK-Cu, but the TGA lists it among unapproved peptide products. Where the therapeutic-goods and cosmetic rules…10 min readLegal status · UKIs GHK-Cu Legal in the UK? Rules and Status (2026)We found no UK law that names GHK-Cu. How cosmetics law and the Human Medicines Regulations 2012 apply to products containing it, and what the MHRA…10 min readLegal status · USIs GHK-Cu Legal in the US? FDA Status and Dates (2026)We found no US law that names GHK-Cu: intended use decides if a product is a cosmetic or a drug. FDA’s compounding status, three recalls and dates.12 min read
Written by 6AM Research. Drafted from the studies and regulator documents listed in the Sources section, where each one is linked; the page is dated. Editorial policy · How we check every page
Research guide · GHK-CuMembers see live batch certificates for GHK-Cu.
Request access